EU Eyes Autumn Approval Of Pfizer Jab For Covid Variants

The EU's drug watchdog said Wednesday it aims to approve this autumn a Pfizer/BioNTech Covid vaccine adapted for two fast-spreading subvariants of the Omicron strain. The BA.4 and BA.5 types are driving a wave of new cases in Europe and the United States, prompting the World Health Organization to warn that the pandemic is nowhere near over. The European Medicines Agency (EMA) said it had launched on Monday a review of an adapted version of the Pfizer jab targeting those two types, which are more US FDA detects probable human EU taps Moderna for more Covid variant jabs Antibodies that can lead to vaccination for all Covid strains found Indian companies eye new trade channels in Pharma pfizer covid world health organization omicron moderna health news transmissible and immune evasive than earlier Covid versions. "EMA is expecting to receive an application for the BA.4/5 adapted vaccine developed by Pfizer/BioNTech, which will be evaluated for a potential rapid approval in the fall," an EMA spokesman told AFP in an emailed statement. That would come "shortly after" the expected approval of two other adapted vaccines by Pfizer and its rival Moderna, which target the original Covid virus and the earlier BA.1 subvariant of Omicron, the spokesman said. Both Pfizer and Moderna had lodged separate applications for approval of those vaccines on July 22, the spokesman said. The EMA has previously said the first Omicron-adapted jabs could be approved as early as September.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!